Preterm Birth Prevention And Management Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Preterm Birth Prevention And Management Market Trends and Insights

Escalating Global Incidence of Preterm Births

Preterm births now affect 13.4 million infants a year, anchoring steady demand across therapeutic and diagnostic segments. Rising maternal age, multiple-birth pregnancies from assisted-reproductive technologies, and persistent care disparities sustain the upward trend. Low- and middle-income countries shoulder the heaviest burden, yet cost pressures are global because life-long care of survivors tops USD 30 billion in annual spending in the United States alone. This epidemiology is driving simultaneous growth in preventive interventions and neonatal intensive-care technologies, reinforcing a dual-growth dynamic that keeps the preterm birth prevention and management market expanding on multiple fronts.

Clinical-Guideline Shift Toward Progesterone Therapy

Professional societies now endorse vaginal progesterone for women with short cervix after the withdrawal of 17-hydroxyprogesterone caproate. The pivotal PREGNANT trial showed a 45% drop in preterm deliveries, eliminating earlier uncertainty and unifying prescribing patterns. Pharmaceutical firms are responding with sustained-release microcrystal formulations that improve adherence, while genetic research is clarifying which patients benefit most. The resulting clarity is channelling capital toward route-of-administration innovation and supports predictable volume growth.

Rapid Uptake of Point-of-Care Biomarker Tests

The shift from subjective assessment to objective biomarker evaluation continues to reshape clinical workflow. The Rapid fFN test delivers results in 10 minutes and registers a 96% negative predictive value, allowing safe discharge of low-risk patients. Parallel advances combine multiple analytes; cell-free RNA signatures can predict preterm birth four months in advance, opening a new prevention window. Growing integration with electronic medical records enables real-time decision support, fuelling the fastest CAGR in the overall preterm birth prevention and management market.

Government Maternal-Health Funding Boosts

Federal spending is expanding. The NIH IMPROVE initiative secured USD 53.4 million for FY2024, and 15 US states received combined grants of USD 19 million for innovative maternal-health projects^[1]. Grant dollars focus on hypertension screening, community-based training, and home-based diagnostics, directly enlarging the addressable market and reducing private-sector risk. Similar policy momentum is emerging in Canada, the United Kingdom, and Japan, laying durable demand foundations for the preterm birth prevention and management market.

FDA Withdrawal of Makena and Tighter Regulations

Regulators pulled 17-hydroxyprogesterone caproate from the market in 2023 after efficacy and safety doubts surfaced, forcing clinicians to redesign treatment protocols and raising evidentiary hurdles for new agents. The action lengthens development timelines and raises capital requirements for future therapeutics, tempering growth momentum in the near term even as it safeguards patient outcomes.

Limited Novel-Drug R&D Investment

High trial-failure rates and ethical complexities around pregnant populations have curbed venture funding for first-in-class molecules. Developers now prioritize repurposed drugs, such as antibiotics under investigation that showed 40% reduction in preterm births in a recent New England Journal of Medicine trial. This incremental approach constrains breakthrough potential but keeps pipeline risk manageable.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Intervention: Diagnostics Mount a Rapid Challenge to Therapeutics

Therapeutics retained leadership with a 60.62% slice of the preterm birth prevention and management market in 2025, anchored by progesterone, calcium channel blockers, and corticosteroids. Vaginal progesterone remains first line, while nifedipine outperforms historic tocolytics in prolonging gestation. Corticosteroids continue to support fetal lung maturation under strict gestational-age windows. Pipeline activity spans oxytocin-receptor antagonists and vasodilator combinations, yet uptake hinges on clearer survival data.

Diagnostics are posting the fastest 9.41% CAGR, fuelled by fibronectin kits, PAMG-1 assays, and cervical-length ultrasound systems that integrate with machine-learning risk-scoring. High negative predictive value shortens hospital stays and guides targeted steroid use, strengthening payer backing. Combined, these trends reinforce the preterm birth prevention and management market as a prevention-first clinical environment.

By Route of Administration: Vaginal Dominance Meets Oral Momentum

Vaginal delivery captured 44.02% share of the preterm birth prevention and management market size in 2025 because local dosing concentrates progesterone where it is needed and minimizes systemic side effects. Self-administration, sustained-release rings, and low storage costs favour further adoption.

Oral formulations are accelerating at 9.62% CAGR, energised by micronization and protective coatings that lift bioavailability to therapeutic thresholds. Patients prefer tablets for convenience, and physicians value simplified prescribing. Parenteral routes retain a corner niche for emergency tocolysis but face user discomfort and higher site-of-care costs.

By End User: Hospitals Remain Anchors as Home Healthcare Expands

Hospitals held 56.68% of revenue in 2025, relying on neonatal intensive-care units and 24 × 7 obstetric teams that manage complex deliveries. Tertiary centres also run most clinical trials, so they keep early access to new technology.

Home healthcare is advancing at 10.65% CAGR thanks to connected devices that transmit uterine-activity and blood-pressure data directly to clinicians. Remote models lower admission rates and improve access in rural settings, thereby enlarging the reach of the preterm birth prevention and management market.

By Gestational-Age Risk Category: Extreme Prematurity Drives Spend

Extremely preterm births accounted for 53.21% of revenue in 2025, and their 9.88% CAGR underscores both clinical need and technological progress. Intensive ventilation, surfactant therapy, and personalised steroid protocols improve survival, justifying resource concentration.

Very preterm (28–32 weeks) and moderate-to-late preterm (32–37 weeks) segments grow steadily as corticosteroid guidelines widen and antenatal care access improves. ACTION-III trial results could broaden corticosteroid use in late-preterm births and increase addressable volumes.

Geography Analysis

North America commanded 41.76% of the preterm birth prevention and management market share in 2025, sustained by reimbursement structures, NIH funding streams, and guideline maturity. Market penetration of rapid biomarker tests and sustained-release progesterone is already high. Regulatory uncertainty after Makena’s withdrawal spurred tighter pharmacovigilance but also nudged clinics toward diagnostically driven care paths.

Asia-Pacific registers the quickest 10.05% CAGR, propelled by broader insurance coverage, government device-approval reforms, and multi-country cohort studies such as CARE-Preterm that standardise neonatal care. China’s expanding NICU network and India’s Single Window regulatory portal are shortening product-rollout timelines, while Japan is integrating vaginal progesterone into routine obstetrics. Collectively, the region is reshaping volume dynamics for the preterm birth prevention and management market.

Europe, the Middle East and Africa, and South America offer incremental upside. EMA’s suspension of 17-hydroxyprogesterone caproate is accelerating adoption of alternative agents. Sub-Saharan Africa remains the highest-incidence region yet faces infrastructure gaps, creating white-space for low-cost diagnostics and telehealth. South American regulators are investing in maternal-health capacity building, helping lift baseline demand.

Regulatory Landscape

Regulation in the preterm birth prevention and management market is being shaped by higher evidence thresholds for pregnancy indications and tighter device conformity rules. In the United States, the FDA withdrawal of 17-hydroxyprogesterone caproate (Makena) in 2023 reset the therapeutic bar for recurrent preterm birth prevention and reinforced reliance on guideline-aligned progesterone pathways and diagnostics that can support risk triage in routine care.

On the device and IVD side, market access continues to rely on established frameworks, but compliance overhead is rising across major regions. The FDA continues to clear OB/GYN devices through the 510(k) pathway (for example, K253403, cleared in December 2025). In Europe, the European Commission MDR/IVDR transition has reached key deadlines, with certain categories requiring full compliance by May 28, 2026. Globally, WHO guidance updates, including its April 2025 recommendations on antenatal corticosteroids for improving preterm birth outcomes, provide a clinical-policy anchor that influences adoption and protocol standardization across health systems.

Value Chain Analysis

The value chain covers discovery and clinical evidence generation, regulated manufacturing, and multi-channel distribution into hospitals, maternity and fertility clinics, and home healthcare settings. On the therapeutics side, the chain is anchored by hormone APIs and finished-dose formulation, notably vaginal progesterone formats, alongside cold-chain and quality systems for pregnancy-use labeling and pharmacovigilance. On the diagnostics side, the chain centers on assay development and validation (including fFN, PAMG-1, and emerging multi-analyte panels), cartridge or kit manufacturing, reader or analyzer placement, and ongoing consumables supply supported by training, quality control, and integration into electronic medical records.

Evidence creation and funding are pivotal upstream steps because pregnant populations require rigorous safety oversight and often face longer trial timelines. For novel device approaches, clinical-stage programs and venture backing provide a bridge from prototyping to pivotal trials and eventual regulatory submissions. For instance, Novocuff raised USD 26 million in July 2024 to advance technology aimed at reducing preterm birth risk, highlighting how capital inflows can support trial execution and manufacturing scale-up, and facilitate channel partnerships with established OB/GYN device and distribution players.

Market Opportunities and Future Outlook

Product whitespace is concentrated in earlier, more actionable risk stratification, and in interventions that can be selected based on biologic subtype rather than broad clinical risk factors alone. February 2026 research validating a three-protein serum biomarker panel (GPX3, NID1, and PAPPA2) for first and second trimester risk assessment highlights a pathway toward earlier screening windows that aligns with the market shift toward prevention-first care, and can expand the role of diagnostics beyond acute triage. Alongside this, point-of-care workflow improvements, including AI-assisted ultrasound approaches discussed in 2026 clinical literature, support demand for integrated platforms that combine imaging, decision support, and rapid testing.

On the therapeutic side, the post-Makena environment creates room for evidence-backed alternatives and adjuncts, with active trial activity indicating where innovation is moving. March of Dimes announced the launch of FLIP-2 in May 2026, a Phase 2b clinical trial evaluating LACTIN-V (a live biotherapeutic product) for preterm birth prevention in high-risk women. An April 2026 ClinicalTrials.gov-registered pilot study (NCT07305519) began recruitment to evaluate a multi-ingredient adjunct alongside vaginal progesterone. Together, these initiatives point to a near-term opportunity for companies that combine targeted therapeutics with biomarker-led patient selection and care pathways that fit hospital and home monitoring models.